Diarmaid Hughes

Diarmaid Hughes

Auto-generated profile, based on publicly available information

Diarmaid Hughes

Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
DHDiarmaid Hughes
Diarmaid Hughes
AAAli Aminian
Ali Aminian
CTChao Tu
Chao Tu
YOYuichiro Okushi
Yuichiro Okushi
YSYoshihito Saijo
Yoshihito Saijo
BXBo Xu
Bo Xu
Background: Obesity leads to an increased risk of cardiovascular disease morbidity and death, including heart failure. Bariatric surgery has been proven to be the most effective long‐term weight management treatment. This study investigated the changes in cardiac structure and function after bariatric surgery, including left ventricular global longitudinal strain. Methods and Results: There were 398 consecutive patients who underwent bariatric surgery with pre‐ and postoperative transthoracic echocardiographic imaging at a US health system between 2004 and 2019. We compared cardiovascular risk factors and echocardiographic parameters between baseline and follow‐up at least 6 months postoperatively. Along with decreases in weight postoperatively, there were significant improvements in cardiovascular risk factors, including reduction in systolic blood pressure levels from 132 mm Hg (25th–75th percentile: 120–148 mm Hg) to 127 mm Hg (115–140 mm Hg; P =0.003), glycated hemoglobin levels from 6.5% (5.9%–7.6%) to 5.7% (5.4%–6.3%; P <0.001), and low‐density lipoprotein levels from 97 mg/dL (74–121 mg/dL) to 86 mg/dL (63–106 mg/dL; P <0.001). Left ventricular mass decreased from 205 g (165–261 g) to 190 g (151–236 g; P <0.001), left ventricular ejection fraction increased from 58% (55%–61%) to 60% (55%–64%; P <0.001), and left ventricular global longitudinal strain improved from −15.7% (−14.3% to −17.5%) to −18.6% (−16.0% to −20.3%; P <0.001) postoperatively. Conclusions: This study has shown the long‐term impact of bariatric surgery on cardiac structure and function, with reductions in left ventricular mass and improvement in left ventricular global longitudinal strain. These findings support the cardiovascular benefits of bariatric surgery.

18 October 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RMRobert P. Murphy
Robert P. Murphy
MOMartin J. O’dOnnell
Martin J. O’dOnnell
ANAoife Nolan
Aoife Nolan
EMEmer R McGrath
Emer R McGrath
AOAengus O’cOnghaile
Aengus O’cOnghaile
CJConor Judge
Conor Judge
Background: A run‐in period may increase adherence to intervention and reduce loss to follow‐up. Whether use of a run‐in period affects the magnitude of treatment effects is unknown. Methods and Results: We conducted a meta‐analysis comparing treatment effects from 11 systematic reviews of cardiovascular prevention trials using a run‐in period with matched trials not using a run‐in period. We matched run‐in with non–run‐in trials by population, intervention, control, and outcome. We calculated a ratio of relative risks (RRRs) using a random‐effects meta‐analysis. Our primary outcome was a composite of cardiovascular events, and the primary analysis was a matched comparison of clinical trials using a run‐in period versus without a run‐in period. We identified 66 run‐in trials and 111 non–run‐in trials (n=668 901). On meta‐analysis there was no statistically significant difference in the magnitude of treatment effect between run‐in trials (relative risk [RR], 0.83 [95% CI, 0.80–0.87]) compared with non–run‐in trials (RR, 0.88 [95% CI, 0.84–0.91]; RRR, 0.95 [95% CI, 0.90–1.01]). There was no significant difference in the RRR for secondary outcomes of all‐cause mortality (RRR, 0.97 [95% CI, 0.91–1.03]) or medication discontinuation because of adverse events (RRR, 1.05 [95% CI, 0.85–1.21]). Post hoc exploratory univariate meta‐regression showed that on average a run‐in period is associated with a statistically significant difference in treatment effect (RRR, 0.94 [95% CI, 0.90–0.99]) for cardiovascular composite outcome, but this was not statistically significant on multivariable meta‐regression analysis (RRR, 0.95 [95% CI, 0.90–1.0]). Conclusions: The use of a run‐in period was not associated with a difference in the magnitude of treatment effect among cardiovascular prevention trials.